PE20221783A1 - Anticuerpos anti-axl y composiciones - Google Patents
Anticuerpos anti-axl y composicionesInfo
- Publication number
- PE20221783A1 PE20221783A1 PE2022001857A PE2022001857A PE20221783A1 PE 20221783 A1 PE20221783 A1 PE 20221783A1 PE 2022001857 A PE2022001857 A PE 2022001857A PE 2022001857 A PE2022001857 A PE 2022001857A PE 20221783 A1 PE20221783 A1 PE 20221783A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- sequences seq
- amino acid
- seq
- acid sequences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invencion se refiere a un anticuerpo o una porcion de union a antigeno de este, que comprende: a) una HC que comprende las secuencias de aminoacidos SEQ ID NO 43 y 61 y una LC que comprende las secuencias de aminoacidos SEQ ID NO 44 y 62, b) una HC que comprende las secuencias de aminoacidos SEQ ID NO 13 y 61 y una LC que comprende las secuencias de aminoacidos SEQ ID NO 14 y 62, entre otras. La cadena pesada de dicho anticuerpo comprende: i) las regiones de complementariedad de cadena pesada (H-CDR 1-3) que comprenden las secuencias SEQ ID NO 45, 46 y 47 y ii) una VH que comprende la secuencia de aminoacidos SEQ ID NO 43. La cadena ligera de dicho anticuerpo comprende: i) las regiones de complementariedad de cadena pesada (L-CDR 1-3) que comprenden las secuencias SEQ ID NO 48, 49 y 50 y ii) una VH que comprende la secuencia de aminoacidos SEQ ID NO 44. Tambien se refiere a una composicion farmaceutica, a una molecula de acido nucleico que codifica dicho anticuerpo, un vector, una celula huesped y un metodo de produccion de dicho anticuerpo. El anticuerpo de la invencion es un anticuerpo recombinante dirigido a AXL, el cual es util en el tratamiento del cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982852P | 2020-02-28 | 2020-02-28 | |
| PCT/IB2021/051636 WO2021171257A1 (en) | 2020-02-28 | 2021-02-26 | Anti-axl antibodies and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221783A1 true PE20221783A1 (es) | 2022-11-16 |
Family
ID=75426640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001857A PE20221783A1 (es) | 2020-02-28 | 2021-02-26 | Anticuerpos anti-axl y composiciones |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11807688B2 (es) |
| EP (1) | EP4110824A1 (es) |
| JP (1) | JP2023515821A (es) |
| KR (1) | KR20220148237A (es) |
| CN (1) | CN115210263A (es) |
| AR (1) | AR121441A1 (es) |
| AU (1) | AU2021225490A1 (es) |
| BR (1) | BR112022015977A2 (es) |
| CA (1) | CA3170975A1 (es) |
| CL (1) | CL2022002259A1 (es) |
| CO (1) | CO2022012159A2 (es) |
| IL (1) | IL295596A (es) |
| MX (1) | MX2022010670A (es) |
| PE (1) | PE20221783A1 (es) |
| TW (1) | TW202146455A (es) |
| WO (1) | WO2021171257A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| BRPI0820543A2 (pt) | 2007-11-15 | 2015-06-16 | Chugai Pharmaceutical Co Ltd | Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo |
| MX336001B (es) | 2010-06-18 | 2016-01-07 | Genentech Inc | Anticuerpos anti-axl y metodos de uso. |
| WO2016097370A2 (en) | 2014-12-18 | 2016-06-23 | Bergen Teknologioverføring As | Anti-axl antagonistic antibodies |
| EP3319993B1 (en) | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| GB201610902D0 (en) | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| EA202092448A1 (ru) | 2018-04-10 | 2021-03-05 | Генмаб А/С | Axl-специфичные антитела для лечения онкологических заболеваний |
-
2021
- 2021-02-26 KR KR1020227033462A patent/KR20220148237A/ko unknown
- 2021-02-26 WO PCT/IB2021/051636 patent/WO2021171257A1/en active Application Filing
- 2021-02-26 BR BR112022015977A patent/BR112022015977A2/pt unknown
- 2021-02-26 MX MX2022010670A patent/MX2022010670A/es unknown
- 2021-02-26 IL IL295596A patent/IL295596A/en unknown
- 2021-02-26 AU AU2021225490A patent/AU2021225490A1/en active Pending
- 2021-02-26 US US17/186,465 patent/US11807688B2/en active Active
- 2021-02-26 JP JP2022551247A patent/JP2023515821A/ja active Pending
- 2021-02-26 AR ARP210100499A patent/AR121441A1/es unknown
- 2021-02-26 PE PE2022001857A patent/PE20221783A1/es unknown
- 2021-02-26 CA CA3170975A patent/CA3170975A1/en active Pending
- 2021-02-26 EP EP21717200.6A patent/EP4110824A1/en active Pending
- 2021-02-26 CN CN202180017213.3A patent/CN115210263A/zh active Pending
- 2021-03-02 TW TW110107402A patent/TW202146455A/zh unknown
-
2022
- 2022-08-18 CL CL2022002259A patent/CL2022002259A1/es unknown
- 2022-08-25 CO CONC2022/0012159A patent/CO2022012159A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210269532A1 (en) | 2021-09-02 |
| JP2023515821A (ja) | 2023-04-14 |
| AR121441A1 (es) | 2022-06-08 |
| CN115210263A (zh) | 2022-10-18 |
| CA3170975A1 (en) | 2021-09-02 |
| BR112022015977A2 (pt) | 2022-10-11 |
| KR20220148237A (ko) | 2022-11-04 |
| CL2022002259A1 (es) | 2023-04-14 |
| IL295596A (en) | 2022-10-01 |
| AU2021225490A1 (en) | 2022-09-15 |
| CO2022012159A2 (es) | 2022-10-31 |
| WO2021171257A1 (en) | 2021-09-02 |
| TW202146455A (zh) | 2021-12-16 |
| US11807688B2 (en) | 2023-11-07 |
| EP4110824A1 (en) | 2023-01-04 |
| MX2022010670A (es) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124240A2 (es) | Un anticuerpo biespecífico anti-vegf / anti-ang-2, ácido nucleico, vector de expresión, célula huésped y un método de preparación del anticuerpo | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| AR127516A2 (es) | VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN | |
| PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| EP4295911A2 (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| PE20141658A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| ES2678696T3 (es) | Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas | |
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| EA201891127A1 (ru) | Нуклеиновые кислоты, кодирующие повторяющиеся аминокислотные последовательности с высоким содержанием пролиновых и аланиновых остатков, имеющие нуклеотидные последовательности с низкой повторяемостью | |
| AR076508A1 (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
| ECSP14011269A (es) | Formulaciones de anticuerpos y proteínas de alta concentración | |
| PE20231511A1 (es) | Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3 | |
| AR095614A1 (es) | Anticuerpos heterodiméricos biespecíficos | |
| NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| AR071232A1 (es) | Proteina hibrida usada como vacuna contra toxinas shiga de e. coli | |
| AR109450A1 (es) | Moléculas de unión a ilt7 y métodos de uso de las mismas | |
| EA201290930A1 (ru) | Растения с улучшенными характеристиками урожайности и способ их получения | |
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 |